MAP2K7 and cancer: SHP2 activation was important resistance mechanism for blockade of MEK in KRAS-mutant cancer, and there were synergy effects between SHP2 and MEK inhibitions in PDOs of PDAC, indicating that the dual SHP2/MEK inhibitors may be applied to the treatment for KRAS-mutant PDAC patients [95].